Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 1
2011 2
2012 1
2013 1
2014 5
2015 6
2016 5
2017 8
2018 14
2019 13
2020 13
2021 23
2022 17
2023 11

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 37648316

101 results

Results by year

Filters applied: . Clear all
Page 1
Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study.
Eule CJ, Hu J, Al-Saad S, Collier K, Boland P, Lewis AR, McKay RR, Narayan V, Bosse D, Mortazavi A, Rose TL, Costello BA, Bryce AH, Lam ET. Eule CJ, et al. Clin Genitourin Cancer. 2023 Aug;21(4):483-490. doi: 10.1016/j.clgc.2023.04.008. Epub 2023 Apr 24. Clin Genitourin Cancer. 2023. PMID: 37193610 Free PMC article.
Clinical features of neuroendocrine prostate cancer.
Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JM, Elemento O, Nanus DM, Tagawa ST, Ballman KV, Beltran H. Conteduca V, et al. Eur J Cancer. 2019 Nov;121:7-18. doi: 10.1016/j.ejca.2019.08.011. Epub 2019 Sep 13. Eur J Cancer. 2019. PMID: 31525487 Free PMC article.
Platinum sensitivity in metastatic prostate cancer: does histology matter?
Humeniuk MS, Gupta RT, Healy P, McNamara M, Ramalingam S, Harrison M, George D, Zhang T, Wu Y, Armstrong AJ. Humeniuk MS, et al. Prostate Cancer Prostatic Dis. 2018 Apr;21(1):92-99. doi: 10.1038/s41391-017-0017-6. Epub 2017 Dec 11. Prostate Cancer Prostatic Dis. 2018. PMID: 29230006
Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance.
Pandya D, Shah M, Kaplan F, Martino C, Levy G, Kazanjian M, Batter S, Martignetti J, Frank RC. Pandya D, et al. Cold Spring Harb Mol Case Stud. 2021 Feb 19;7(1):a005801. doi: 10.1101/mcs.a005801. Print 2021 Feb. Cold Spring Harb Mol Case Stud. 2021. PMID: 33608381 Free PMC article.
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, Manyam GC, Korentzelos D, Park S, Tang Z, Wu C, Dong Z, Sigouros M, Sboner A, Beltran H, Chen Y, Corn PG, Tetzlaff MT, Troncoso P, Broom B, Thompson TC. Liu B, et al. Clin Cancer Res. 2019 Nov 15;25(22):6839-6851. doi: 10.1158/1078-0432.CCR-19-0317. Epub 2019 Aug 22. Clin Cancer Res. 2019. PMID: 31439587 Free PMC article.
Treatment Outcomes in Neuroendocrine Prostate Cancer.
Iwamoto H, Nakagawa R, Makino T, Kadomoto S, Yaegashi H, Nohara T, Shigehara K, Izumi K, Kadono Y, Mizokami A. Iwamoto H, et al. Anticancer Res. 2022 Apr;42(4):2167-2176. doi: 10.21873/anticanres.15699. Anticancer Res. 2022. PMID: 35347041
101 results